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Objective: To reveal the present status and future directions of colorectal cancer in Asia.
Methods: The Working Group consisted of oncologists from six Asian countries (Japan,
Korea, Hong Kong, China, Taiwan, Singapore and Philippines) discussed colorectal cancer in
the 30th Asia-Pacific Cancer Conference and made a consensus report.
Results: The incidence of colorectal cancer has been increasing rapidly in recent decades,
and mortality has also increased except in Japan and Singapore. Colorectal screening with
fecal occult blood tests is a national policy in Taiwan, Japan and Korea. Total colonoscopy is
the most common examination for diagnosing colorectal cancers and neoplasms. However,
there are differences in the macroscopic classification used. Laparoscopic surgery for colon
cancer is extensively used, although the indication varies. Adequate lymph node harvesting of
more than 12 nodes is performed in most countries. Neoadjuvant chemoradiation therapy is
not routinely done for T2 or T3 rectal cancer. Total mesorectal excision is the standard surgery
for rectal cancer. Survival rate data are unavailable for many countries and should be compiled
in all. The differences in the health-care delivery systems affect the treatment choices for unre-
sectable colorectal cancer. Infusional 5-FU plus leucovorin plus oxaliplatin (FOLFOX) is the
most popular first-line regimen. Cetuximab is mainly used as a second- or third-line regimen
with reference to k-ras mutation. Oxaliplatin-based adjuvant chemotherapy is commonly used
for stage III disease, whereas the clinical practice for stage II disease varies.
Conclusions: Further clinical cooperation is needed to optimize the management of colorectal
cancer in Asia.
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INTRODUCTION
The Working Group, consisting of 12 expert oncologists for
colorectal cancer from six Asian countries (Japan, Korea,
Hong Kong, China, Taiwan, Singapore and Philippines), dis-
cussed screening, diagnosis, surgery and chemotherapy, based
on their reply to a questionnaire (appendix). Dr Suzuki (the
secretary of this working group) had made the questionnaire
and sent it to all members (authors of this manuscript) of the
working group in advance. Then, he obtained their replies
and summarized the results as a the material of the meeting in
the 30th Asia-Paciﬁc Cancer Conference (APCC). The discus-
sion points were the following: (i) incidence, mortality rate
and cancer screening, (ii) endoscopy, (iii) surgery and (iv)
chemotherapy for colorectal cancer.
# The Author (2010). Published by Oxford University Press. All rights reserved.
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INCIDENCE, MORTALITY RATE AND CANCER
SCREENING
The incidence of colorectal cancer has been increasing
rapidly in the Asian area in the last few decades. The mor-
tality of colorectal cancer has been increasing in the last
decade in Asian countries, except in Japan and Singapore
(Fig. 1). Colorectal cancer screening systems have been
launched as a national policy in Taiwan, Japan and Korea,
but national screening programs do not exist in some Asian
countries. Screening is conducted for males and females
who are 40 years old or more in Japan and at least 50 years
old in Korea. In Taiwan, the target age for screening is from
50 to 69 years of age. Immunological or chemical fecal
occult blood tests are used as the screening methods. For
more detailed examination, total colonoscopy is conducted
as the method of ﬁrst choice. In Taiwan and Japan, the col-
orectal screening rate for the local population is 25%.
Colorectal cancer screening can decrease mortality (1),
however, the screening rate in Asia is quite low compared
with Western countries (2).
Fecal occult blood tests for screening and total colono-
scopy for close examination should be recommended in
countries with a high prevalence of colorectal cancer.
Budget support from all sectors is needed for colorectal
cancer screening. Education and advocacy to the public need
to be strengthened.
COLORECTAL ENDOSCOPY
Colonoscopy is now the most widely accepted and popular
examination for diagnosis of colorectal cancer, and total
colonoscopy is also the common pathway and goal of all
screening tests. The macroscopic morphology is directly
linked to the biological behavior and the risk of malignant
transformation or deep invasion of colorectal neoplasms (3).
Both the Paris classiﬁcation and the Japanese classiﬁcation
are popular for classiﬁcation of superﬁcial GI tract
neoplasms. Depressed-type colorectal neoplasms carry a
higher risk of malignant transformation and they invade
deep into the submucosal layer even when still relatively
small in size, compared with ﬂat or polypoid colorectal neo-
plasms. A survey of the application of macroscopic classiﬁ-
cation in Asian countries showed that Hong Kong, Taiwan,
Japan and Korea widely use macroscopic or endoscopic
classiﬁcation, whereas Singapore and the Philippines do not
use macroscopic classiﬁcation in colonoscopic examinations.
The Japanese classiﬁcation is more popular in Japan,
whereas the Paris classiﬁcation that was published in 2002 is
more popular in Korea. Both classiﬁcation systems are
widely used in Taiwan.
Colorectal endoscopy is important for delineating the
margin and determining the surface characteristics of color-
ectal neoplasms. After magniﬁcation or dye spraying, endo-
scopy can deﬁne the area of malignant transformation and,
moreover, can predict the depth of invasion, which deter-
mines the optimal treatment strategy. The survey found that
the modality used to diagnose or predict the depth of inva-
sion of colorectal cancer differs among countries. Most
countries use biopsy as the gold standard, but in Taiwan and
Japan the dye-spraying method and magniﬁed observation
are more popular for characterizing the nature of colorectal
neoplasms.
Polypectomy is the most widely used procedure for resect-
ing colorectal neoplasms. Endoscopic mucosal resection is
popular in most countries, whereas endoscopic submucosal
dissection is less common but used more in Japan and
Korea. Analysis of surgical pathological specimens in Japan
showed that the risk of local lymph node metastasis is near
zero if the depth of invasion is ,1000 mm (4). In both
Japan and Korea, if the depth of invasion is ,1000 mm and
the lesion is a histologically well-differentiated adenocarci-
noma, it is acceptable to perform endoscopic resection, and
further surgical resection is not necessary. In Singapore,
mainly the depth of invasion and the Haggitt classiﬁcation
are used to determine whether surgical resection is necessary
or not.
Figure 1. Age-adjusted mortality of colorectal cancer in Asia.
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In conclusion, total colonoscopy is currently the most
widely used examination to diagnose colorectal cancers and
neoplasms in the Asia-Paciﬁc region. However, there
are some differences and a lack of consensus regarding
macroscopic classiﬁcation of colorectal neoplasms among
countries. The modality that is used to characterize and diag-
nose colorectal neoplasms also differs among countries. To
unify and standardize the endoscopic diagnosis and treatment
procedure for colorectal cancer, a common guideline would
be required in the Asia-Paciﬁc region. Also, the quality of
colonoscopy should be emphasized.
SURGERY
Laparoscopic surgery is actively performed in three
countries, Singapore, Japan and Korea; yet, many colorectal
surgeons in Hong Kong are also experienced in it. As for the
indication, Singapore, the Philippines and Korea usually
perform colon resection for most patients using laparoscopic
techniques. The exception is extremely difﬁcult cases, such
as T4, intestinal obstruction, a history of previous laparot-
omy, etc. However, especially in Japan, laparoscopic surgery
is currently recommended only for T1 or T2 tumor of colon
and rectum, and not for low rectal cancer. The penetration
rate was only 10% in the Philippines, in contrast to around a
50% rate in Korea and 60% in Japan. In four countries,
Singapore, Hong Kong, Japan and Korea, they usually
harvest more than 12 lymph nodes in the usual colectomy,
but in the Philippines they usually harvest ,12 nodes. For
clinical T2 or T3 rectal cancer, most surgeons in Asia do not
usually recommend preoperative chemoradiation. Regarding
the extent of lymph node dissection in rectal cancer, the sur-
geons in Singapore, Hong Kong and Japan usually perform
lateral lymph node dissection for T3 rectal cancer, but the
surgeons in the Philippines and Korea do not. Total mesorec-
tal excision (TME) for rectal cancer is the afﬁrmatively stan-
dard operation. With regard to the 5-year survival rates for
colorectal cancer, they are similar for stage I and stage II,
for example, around a 90% 5-year survival rate for stage I
and an 80% 5-year survival rate for stage II in Japan and
Korea (Table 1). However, there was some difference in the
two countries’ results for stage III colorectal cancer. In
Japan, the 5-year survival rate is over 70%, compared with a
lower rate of around 50% in Korea.
In conclusion, laparoscopic surgery for colon cancer is
widely performed, although the indication varies among
the countries. Second, adequate lymph node harvesting is
generally performed in most countries. Third, neoadjuvant
chemoradiation therapy is not routinely done for T2 or T3
rectal cancer. Fourth, TME is the standard surgery for rectal
cancer. Fifth, survival rate data are not available for many
countries other than Japan and Korea.
The consensus and recommendations regarding the future
strategy for colorectal cancer surgery in Asian countries are
that nationwide exact data should be compiled in all
countries, clinical trials are needed to evaluate the respective
roles of preoperative chemoradiation and lateral pelvic node
dissection, and the surgical techniques for colorectal cancer
need to be standardized.
CHEMOTHERAPY
Much evidence has been generated in Western countries by
large clinical trials, and there are some guidelines for
chemotherapy of colorectal cancer (5). For unresectable
metastatic colorectal cancer, 5-FU plus leucovorin plus
oxaliplatin (FOLFOX) plus bevacizumab or infusional
5-FU plus leucovorin plus irinotecan (FOLFIRI) plus beva-
cizumab is recommended in the western guidelines, but in
Asia the prevalence of use is 30–40% only in Japan
(Table 2). In other countries, the most popular regimen is
FOLFOX without bevacizumab. In Singapore, the preva-
lence of use is very similar for each regimen. Selection of
the treatment regimen is affected by the medical fees. In
Japan, all valid therapies are covered by social medical
insurance, whereas in other countries the patients have to
pay for themselves. In most countries, cetuximab is placed
as a second-line or third-line treatment, with or without iri-
notecan. Patients with mutant-type K-Ras gene get no
beneﬁt from cetuximab (5). Therefore, K-Ras mutations are
checked before using cetuximab in almost all countries, but
not in Japan, where the K-Ras mutation test has not yet
Table 1. Five-year survival rates of colorectal cancer
Stage I (%) Stage II (%) Stage III (%) Stage IV (%)
C R T C R T C R T C R T
Taiwan 85.3 73.1 – 75.5 65.1 – 47.8 56.4 – 10.3 12.5 –
Japan 90.6 89.3 90.6 83.6 76.4 81.2 71.3 58.2 66.3 14.3 11.1 13.2
Korea – – 90 – – 70 – – 50 – – .5
Stage I, T1,2N0M0; Stage II, T3,4N0M0; Stage III, TanyN1,2M0; Stage IV, TanyNanyM1; C, Colon; R, Rectum; T, Total.
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been approved. With regard to the adjuvant chemotherapy
for colon cancer, stage II and III disease were handled sep-
arately (Table 3). In most countries, a 5-FU-based regimen,
not containing oxaliplatin, is routinely used for the adjuvant
setting for stage II colon cancer. For stage III colon cancer,
most countries except for Japan use a FOLFOX or XELOX
regimen. The reason for this discrepancy is that FOLFOX
for the adjuvant setting has been just approved in Japan
in October 2009. The duration of adjuvant therapy was
6 months in all countries.
In conclusion, differences in the health-care delivery
systems signiﬁcantly affect the treatment choices for unre-
sectable colorectal cancer. FOLFOX is the most popular
ﬁrst-line regimen for unresectable and metastatic colorectal
cancer. Cetuximab is mainly used as the second- or third-
line regimen, with or without irinotecan. K-Ras mutation
testing is usually performed before cetuximab use.
Oxaliplatin-based adjuvant chemotherapy is commonly used
for stage III colon disease, whereas the clinical practice for
stage II disease varies among the countries.
In conclusion, clinical cooperation is strongly needed to
optimize the management of colorectal cancer in Asia.
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Table 2. Proportions (%) of the ﬁrst-line regimen for unresectable metastatic colorectal
Singapore Philippines Hong Kong Taiwan Japan Korea
5-FU/LV 10 25 10 10 3–5
5-FU/LV þ bevacizumab 0 5 0 0–2
FOLFOX 25 50 40 50 40–60 60
FOLFOX þ bevacizumab 10 6 5 5 25–35 5
FOLFIRI 25 5 40 20 5 15
FOLFIRI þ bevacizumab 10 4 5 5 5 3
XELOX 10 15
SOL 1–5
XELOX þ bevacizumab 10
UFT þ LV 5 1
FOLFOX or FOLFIRI þ cetuximab 10 2
5-FU, 5-ﬂuorouracil; LV, leucovorin; XELOX, capecitabin plus oxaliplatin; SOL, S-1 plus oxaliplatin.
Table 3. The most popular adjuvant chemotherapy for colon cancer in each country
Singapore Philippines Hong Kong Taiwan Japan Korea
Stage II 5-FU/LV, capecitabine FOLFOX 5-FU/LV 5-FU/LV UFT 5-FU/LV (low risk), FOLFOX,
capecitabine (high risk)
Stage III FOLFOX, XELOX FOLFOX 5-FU/LV, FOLFOX FOLFOX 5-FU/LV, UFT/LV,
capecitabine
FOLFOX, capecitabine
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